Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings for Xenetic Biosciences, Inc. (XBIO)
Earnings in 2023 (TTM): $-4,134,578
According to Xenetic Biosciences, Inc.'s latest financial reports the company's current earnings (TTM) are $-4,134,578. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Xenetic Biosciences, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-4,134,578 | $-4,134,578 |
| 2022 | $-6,552,353 | $-6,386,798 |
| 2021 | $-5,645,179 | $-5,544,712 |
| 2020 | $-13,811,984 | $-10,893,466 |
| 2019 | $-12,775,025 | $-15,949,915 |
| 2018 | $-7,300,458 | $-7,300,458 |
| 2017 | $-3,595,132 | $-3,595,132 |
| 2016 | $-54,206,106 | $-54,206,106 |
| 2015 | $-12,507,471 | $-12,507,471 |
| 2014 | $-14,307,104 | $-14,307,104 |
| 2013 | $-8,579,246 | $-8,579,246 |
| 2012 | $-6,328,340 | $-6,328,340 |